Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 401–500 of 1,001
CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target
Malik, S., Westcott, J. M., Brekken, R. A., & Burrows, F. J. (2021) · Cancers · doi:10.3390/cancers14010086 · Cited by 44
Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins
Stone, M. L., Lee, J., Lee, J. W., Coho, H., Tariveranmoshabad, M., Wattenberg, M. M., Choi, H., Herrera, V. M., Xue, Y., Choi-Bose, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01820-1 · Cited by 42
Self-citationPing-Pong—Tumor and Host in Pancreatic Cancer Progression
Mu, W., Wang, Z., & Zöller, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01359 · Cited by 38
Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria
Aindelis, G., & Chlichlia, K. (2020) · Vaccines · doi:10.3390/vaccines8020329 · Cited by 43
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 42
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions
Montironi, C., Muñoz‐Pinedo, C., & Eldering, E. (2021) · Cancers · doi:10.3390/cancers13020284 · Cited by 40
Chen, X., Chen, H., He, D., Cheng, Y., Zhu, Y., Xiao, M., Lan, H., Wang, Z., & Cao, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672158 · Cited by 49
Boesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005401 · Cited by 38
The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome
Xue, X., Li, R., Chen, Z., Li, G., Liu, B., Guo, S., Yue, Q., Yang, S., Xie, L., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235827 · Cited by 39
Self-citationImmunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y., Huang, D., & Yang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.045 · Cited by 40
Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma
Tauber, C., Schultheiß, M., Luca, R. D., Buettner, N., Llewellyn‐Lacey, S., Emmerich, F., Zehe, S., Price, D. A., Neumann‐Haefelin, C., Schmitt-Graeff, A. H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27146 · Cited by 36
Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
Leng, Q., Tarbe, M., Long, Q., & Wang, F. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1111 · Cited by 39
Dhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 39
Self-citationNeoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022) · Vaccines · doi:10.3390/vaccines10020196 · Cited by 40
Lozenov, S., Krastev, B. M., Nikolaev, G., Peshevska-Sekulovska, M., Peruhova, M., & Velikova, T. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065978 · Cited by 36
Naeini, M. M., Newell, F., Aoude, L. G., Bonazzi, V., Patel, K., Lampe, G., Koufariotis, L. T., Lakis, V., Addala, V., Kondrashova, O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38891-x · Cited by 38
Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe
Panuzzo, C., Jovanovski, A., Pergolizzi, B., Pironi, L., Stanga, S., Fava, C., & Cilloni, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113928 · Cited by 37
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
cGAS-STING pathway expression as a prognostic tool in NSCLC
Gammelgaard, K. R., Sandfeld‐Paulsen, B., Godsk, S. H., Demuth, C., Meldgaard, P., Sørensen, B. S., & Jakobsen, M. R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-524 · Cited by 39
Wattenberg, M. M., Herrera, V. M., Giannone, M. A., Gladney, W. L., Carpenter, E. L., & Beatty, G. L. (2021) · JCI Insight · doi:10.1172/jci.insight.145389 · Cited by 38
Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment
Ansari, D., Frieß, H., Bauden, M. P., Samnegård, J., & Andersson, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.24019 · Cited by 38
The Tumor Microenvironment of Pancreatic Cancer
Karamitopoulou, E. (2020) · Cancers · doi:10.3390/cancers12103076 · Cited by 40
Zhuang, Y.-P., Zhou, H., Chen, H., Zheng, M.-Y., Liang, Y., Gu, Y.-T., Li, W., Qiu, W., & Zhou, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115040 · Cited by 37
Microbiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
Zhong, P., Nakata, K., Oyama, K., Higashijima, N., Sagara, A., Date, S., Luo, H., Hayashi, M., Kubo, A., Wu, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03060-5 · Cited by 38
MUC16: clinical targets with great potential
Zhang, X.-Y., Hong, L., & Ling, Z. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01365-5 · Cited by 33
Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Kinny‐Köster, B., Habib, J. R., Wolfgang, C. L., He, J. P., & Javed, A. A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-426 · Cited by 35
Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer
Wandmacher, A. M., Letsch, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13164235 · Cited by 38
Queen, J., Shaikh, F. Y., & Sears, C. L. (2023) · Nature Cancer · doi:10.1038/s43018-023-00602-2 · Cited by 36
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 42
Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors
Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 37
Koemans, W. J., Chalabi, M., van Sandick, J. W., van Dieren, J. M., & Kodach, L. L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.001 · Cited by 34
Zhang, W., Tang, Y., Guo, Y., Kong, Y., Shi, F., Sheng, C., Wang, S., & Wang, Q. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00292-6 · Cited by 35
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
Specht, G., Roetschke, H. P., Mansurkhodzhaev, A., Henklein, P., Textoris‐Taube, K., Urlaub, H., Mishto, M., & Liepe, J. (2020) · Scientific Data · doi:10.1038/s41597-020-0487-6 · Cited by 33
Advances in immunotherapy for pancreatic ductal adenocarcinoma
Miyazawa, M., Katsuda, M., Kawai, M., Hirono, S., Okada, K., Kitahata, Y., & Yamaue, H. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.944 · Cited by 33
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaïb, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 39
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved
Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 32
Zhai, Y., Lu, Q., Lou, T., Cao, G., Wang, S., & Zhang, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6388 · Cited by 31
Immunotherapy for pancreatic ductal adenocarcinoma
Carpenter, E. S., Nelson, S., Bednar, F., Cho, C. S., Nathan, H., Sahai, V., di Magliano, M. P., & Frankel, T. L. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26312 · Cited by 38
Xiao, M., Liang, X.-J., Yan, Z., Chen, J., Zhu, Y., Xie, Y., Li, Y., Li, X., Gao, Q., Feng, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.803962 · Cited by 38
Tumor-resident microbes: the new kids on the microenvironment block
Li, L., Chandra, V., & McAllister, F. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2023.12.002 · Cited by 30
Luo, X., McAndrews, K. M., Arian, K. A., Morse, S. J., Boeker, V., Kumbhar, S. V., Hu, Y., Mahadevan, K. K., Church, K. A., Chitta, S., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.017 · Cited by 30
ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis
Xu, H., Hu, R., Dong, X., Kuang, L., Zhang, W., Tu, C., Li, Z., & Zhao, Z. (2024) · Nature Communications · doi:10.1038/s41467-024-53296-0 · Cited by 40
Shen, Q., Liu, J., Zeng, L., Ren, Y., Liao, J., Chen, S., Tang, Y., Zhang, Z., Jiang, M., Liao, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113588 · Cited by 35
Integrating Experiment and Theory to Understand TCR-pMHC Dynamics
Buckle, A. M., & Borg, N. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02898 · Cited by 32
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming
Diamond, M. S., Lin, J., & Vonderheide, R. H. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0785 · Cited by 30
Michaud, D. E., Mirlekar, B., Steward, C. R., Bishop, G. A., & Pylayeva‐Gupta, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745873 · Cited by 36
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 33
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu, L., Ma, W., Johnson, C. H., Khan, S. A., Irwin, M. L., & Pusztai, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.048 · Cited by 33
Targeting autophagy as a therapeutic strategy against pancreatic cancer
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01889-1 · Cited by 29
Graziano, V., Dannhorn, A., Hulme, H., Williamson, K., Buckley, H., Karim, S. A., Wilson, M., Lee, S. Y., Kaistha, B. P., Islam, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006457 · Cited by 213
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Shao, W., Yao, Y., Yang, L., Li, X., Ge, T., Zheng, Y., Zhu, Q., Ge, S., Gu, X., Jia, R., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00504-8 · Cited by 33
Roerden, M., Castro, A., Cui, Y., Harake, N., Kim, B., Dye, J., Maiorino, L., White, F. M., Irvine, D. J., Litchfield, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010249 · Cited by 36
Cencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03263-w · Cited by 32
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease
Filippini, D., D’Agosto, S. L., Delfino, P., Simbolo, M., Piro, G., Rusev, B. C., Veghini, L., Cantù, C., Lupo, F., Ugel, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48663-7 · Cited by 31
Gut Microbiota and Cancer of the Host: Colliding Interests
Baffy, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_5 · Cited by 33
Fan, K., Wang, J., Sun, W., Shen, S., Ni, X., Gong, Z., Zheng, B., Gao, Z., Ni, X., Suo, T., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112118 · Cited by 32
Zaidi, N., Soban, M., Chen, F., Kinkead, H. L., Mathew, J., Yarchoan, M. M., Armstrong, T. D., Haider, S. M., & Jaffee, E. M. (2020) · JCI Insight · doi:10.1172/jci.insight.136991 · Cited by 29
McGuigan, A. J., Coleman, H. G., McCain, R. S., Kelly, P. J., Johnston, D. I., Taylor, M., & Turkington, R. C. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.192 · Cited by 40
Heij, L. R., Tan, X., Kather, J. N., Niehues, J., Sivakumar, S., Heussen, N. M., van der Kroft, G., Damink, S. W. M. O., Lang, S. A., Bednarsch, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030490 · Cited by 29
Jonckheere, N., Vincent, A., Neve, B., & SEUNINGEN, I. V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188538 · Cited by 33
Li, J., Shi, Z., Liu, F., Fang, X., Cao, K., Meng, Y., Zhang, H., Yu, J., Feng, X., Li, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671333 · Cited by 31
You, L., Zhou, J., Xin, Z., Hauck, J. S., Na, F., Tang, J., Zhou, X., Lei, Z., & Ying, B. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac005 · Cited by 35
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 38
Self-citationMicrobiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Zhou, P., Hu, Y., Wang, X., Shen, L., Liao, X., Zhu, Y., Yu, J., Zhao, F., Zhou, Y., Shen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877939 · Cited by 31
Benkhaled, S., Peters, C., Jullian, N., Arsenijevic, T., Navez, J., Gestel, D. V., Moretti, L., Laethem, J. V., & Bouchart, C. (2023) · Cancers · doi:10.3390/cancers15030768 · Cited by 30
Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response
Chai, Y., Huang, Z., Shen, X., Lin, T., Zhang, Y., Xu, F., Mao, Q., & Liang, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11051240 · Cited by 29
Shukla, G. S., Sun, Y., Pero, S. C., Sholler, G. L. S., & Krag, D. N. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.06.009 · Cited by 30
ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection
Li, Y., Wang, G., Tan, X., Ouyang, J., Zhang, M., Song, X., Liu, Q., Leng, Q., Chen, L., & Xie, L. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0683-4 · Cited by 32
Zhu, S., Zhang, C., Cao, D., Bai, J., Yu, S., Chen, J., Wang, J., Ren, T., Yang, J., Yu, M. Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02277-y · Cited by 29
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
Baleeiro, R. B., Liu, P., Chard, L. S., Gioia, C. D., Nagano, A., Cutmore, L. C., Wang, J., Chelala, C., Nyambura, L. W., Walden, P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007336 · Cited by 35
Ali, L. R., Lenehan, P. J., Cardot‐Ruffino, V., Costa, A. D., Katz, M. H. G., Bauer, T. W., Nowak, J. A., Wolpin, B. M., Abrams, T. A., Patel, A. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1444 · Cited by 31
Ascierto, P. A., Bifulco, C. B., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0798-3 · Cited by 31
Zhang, B., Meng, M., Xiang, S., Cao, Z., Xu, X., Zhao, Z., Zhang, T., Chen, B., Yang, P., Li, Y., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.010 · Cited by 30
The Landscape of Tumor-Specific Antigens in Colorectal Cancer
Bakarurraini, N. A. A. R., Mutalib, N. A., Jamal, R., & Abu, N. (2020) · Vaccines · doi:10.3390/vaccines8030371 · Cited by 33
Oshi, M., Tokumaru, Y., Patel, A. P., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12123635 · Cited by 28
Sacdalan, D. B., & Lucero, J. A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s278089 · Cited by 28
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 35
Merali, N., Chouari, T. A. M., Kayani, K., Rayner, C. J., Jiménez, J. I., Krell, J., Giovannetti, E., Bagwan, I., Relph, K., Rockall, T., et al. (2022) · Cancers · doi:10.3390/cancers14041020 · Cited by 29
Profiling the immune landscape in mucinous ovarian carcinoma
Meagher, N. S., Hamilton, P. T., Milne, K., Thornton, S., Harris, B., Weir, A. L., Alsop, J., Bisinotto, C., Brenton, J. D., Brooks-Wilson, A. R., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.022 · Cited by 31
Molecular principles of tissue invasion and metastasis
Dhanisha, S. S., & Guruvayoorappan, C. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00348.2022 · Cited by 31
Shi, Y., Jing, B., & Xi, R. (2023) · Genome biology · doi:10.1186/s13059-023-03005-9 · Cited by 33
da Silva, M. K., Campos, D. M. D. O., Akash, S., Akter, S., Leow, C. Y., Fulco, U. L., & Oliveira, J. I. N. (2023) · Viruses · doi:10.3390/v15102130 · Cited by 30
Characterization of pancreatic cancer with ultra-low tumor mutational burden
Imamura, T., Ashida, R., Ohshima, K., Uesaka, K., Sugiura, T., Ohgi, K., Yamada, M., Otsuka, S., Hatakeyama, K., Nagashima, T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31579-8 · Cited by 30
Advances and challenges in neoantigen prediction for cancer immunotherapy
Zhang, Y., Chen, T., Li, X., Lan, A., Ji, P.-F., Zhu, Y., & Ma, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617654 · Cited by 48
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 32
Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 31
Neoantigen landscape in metastatic nasopharyngeal carcinoma
Lin, M. F., Zhang, X., You, R., Yang, Q., Zou, X., Yu, K., Liu, Y., Zou, R., Hua, Y., Huang, P., et al. (2021) · Theranostics · doi:10.7150/thno.53229 · Cited by 31
Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy
Deyhle, M. R., Callaway, C. S., Neyroud, D., D’Lugos, A. C., Judge, S. M., & Judge, A. R. (2022) · Cells · doi:10.3390/cells11121893 · Cited by 31
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 31
ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction
Chuwdhury, G. S., Guo, Y., Chiang, C., Lam, K. O., Kam, N., Liu, Z., & Dai, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae024 · Cited by 31
Luca, R. D., & Neri, D. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2194-0 · Cited by 28
Visual Analytics of a Computer-Aided Diagnosis System for Pancreatic Lesions
Dmitriev, K., Marino, J., Baker, K. D., & Kaufman, A. E. (2019) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2019.2947037 · Cited by 28
Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer
Li, T., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188384 · Cited by 27
Personal Neoantigen Vaccines for the Treatment of Cancer
Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 30
Heumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 28
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 27
Extracellular matrix modulates T cell clearance of malignant cells in vitro
Robertson, C., Sebastian, A., Hinckley, A., Rios‐Arce, N. D., Hynes, W. F., Edwards, S. A., He, W., Hum, N. R., Wheeler, E. K., Loots, G. G., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121378 · Cited by 30
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.